Page 2 - Ingmar Hoerr News Today

Covid vaccine from Germany´s CureVac just 48% effective By Thursday Jul 01, 2021 FRANKFURT: Germany´s CureVac said Wednesday that final trial results showed its coronavirus vaccine had an efficacy rate of just 48 percent, far lower than those developed by mRNA rivals BioNTech/Pfizer and Moderna. The outcome had been expected after poor interim data were released earlier this month. The company in part blamed "the unprecedented context of 15 strains circulating" among the trial volunteers, a...

26. Juni 2021, 09:34 Uhr Ingmar Hoerr forschte zwanzig Jahre lang an der RNA-Technologie und wurde dafür nun mit dem Deutschen Innovationspreis ausgezeichnet. Im Podcast beschreibt er, wie sich Krebs ähnlich wie das Coronavirus besiegen lässt. Artikel teilen per: Artikel teilen per: Ingmar Hoerr legt 1999 an der Universität Tübingen im Rahmen seiner Doktorarbeit eine Grundlage für die aktuelle Impfstoffforschung. Ein Jahr später gehört er zu den Mitgründern von Cureva...

(Foto: Sebastian Gollnow/dpa) Investoren und Geschäftsführung der Tübinger Biotech-Firma Curevac treffen am Donnerstag aufeinander. Dabei dürfte auch die Frage aufkommen, wie es mit dem Corona-Impfstoff nun weitergeht. Tübingen (dpa/lsw) - Das Tübinger Biopharma-Unternehmen Curevac trifft sich am heutigen Nachmittag (14.00 Uhr) zu seiner Online-Hauptversammlung. Neben der Diskussion über das Geschäftsjahr 2020 und die Besetzung von Posten wird die Investoren voraussichtl...

PIXABAY/ MANILA BULLETIN “CVnCoV demonstrated an interim vaccine efficacy of 47 percent against Covid-19 disease of any severity and did not meet prespecified statistical success criteria,” CureVac said in a statement. The company blamed the “unprecedented context of at least 13 variants circulating within the study population subset assessed” for the disappointing result, as well as varying responses across different age groups. CureVac said it had communicated the results of the Ph...

A coronavirus vaccine being developed by Germany's CureVac is facing delays as its late-stage trial is slowed by the wait for enough participants to catch COVID

A coronavirus vaccine being developed by Germany's CureVac is facing delays as its late-stage trial is slowed by the wait for enough participants to catch Covid, officials said Friday.

Curevac investor sees bright future for German vaccine maker Friedrich von Bohlen believes equity and incentives can intensify medical innovation about 6 hours ago   Two centuries ago, Friedrich Krupp, a struggling German inventor and would-be industrialist, was not yet 40 when he died in debt, leaving behind a wife, four children and an unrealised dream. It fell to his son Alfred Krupp to harvest the seeds he had planted and lead a revolution that saw imperial Germany steal Victorian Britain...

DER SPIEGEL Suche öffnen BioNTech, CureVac and Co. Patent Suspensions Threaten Germanys Booming Biotech Industry With their next-generation mRNA vaccines, the German companies BioNTech and CureVac are at the forefront of pharmaceutical innovation. But U.S. President Joe Bidens plan to suspend patent protections is threatening that position. Şahin: Their company is also working on vaccines against the flu and cancer. Foto:  Ramon Haindl Usually, hindsight is necessary to identify the moment ...

Covid 19 coronavirus: This new vaccine could bring hope to the unvaccinated world 5 May, 2021 08:46 PM 10 minutes to read Curevacs headquarters in Tuebingen, Germany. Photo / AP New York Times By: Carl Zimmer The German company CureVac hopes its RNA vaccine will rival those made by Moderna and Pfizer-BioNTech. It could be ready next month. In early 2020, dozens of scientific teams scrambled to make a vaccine for Covid-19. Some chose tried-and-true techniques, such as making va...

A year ago, Gaithersburg, Maryland-based Novavax Inc. (NASDAQ:NVAX) was a struggling biotech company; fast forward to the present and NVAX is 2,500% more valuable than it was 12 months ago, thanks mainly to its very promising Covid-19 vaccine candidate, NVX-CoV2373. A few days ago, Novavax announced that clinical tests had shown that its coronavirus vaccine was 96.4% effective against mild, moderate and severe cases of Covid-19 caused by the original strain and also 48.6% effective in a midsta...